Study guide
13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
Key Takeaways Explain This Topic AI
Preeclampsia with severe features (BP ≥160/110 mmHg, thrombocytopenia, elevated AST/ALT, renal insufficiency, pulmonary edema, or persistent cerebral/visual symptoms) and eclampsia require immediate seizure prophylaxis with intravenous magnesium sulfate (4-6 g loading dose over 15-20 min, then 1-2 g/h infusion for ≥24 hours postpartum).
Clinical monitoring for hypermagnesemia is essential: patellar reflexes are lost at about 9–12 mg/dL, respiratory depression appears around 12–18 mg/dL, conduction changes above about 18 mg/dL, and cardiac arrest occurs at about 25–30 mg/dL; acute magnesium toxicity is immediately reversed with 10% calcium gluconate 1 g (10 mL) IV over 3-5 minutes.
Acute severe gestational hypertension must be lowered within 30-60 minutes using IV labetalol, IV hydralazine, or oral immediate-release nifedipine; ACE inhibitors, ARBs, and direct renin inhibitors are strictly contraindicated due to fatal fetopathy and renal dysgenesis.
Postpartum hemorrhage (PPH) pharmacotherapy follows a strict stepwise escalation: IV oxytocin infusion is first-line; methylergonovine is strictly contraindicated in hypertension/preeclampsia; carboprost tromethamine is strictly contraindicated in active asthma; and misoprostol serves as sublingual/rectal backup.
The landmark WOMAN trial established that tranexamic acid (1 g IV over 10 min within 3 hours of birth, repeatable once after 30 min) significantly reduces death from postpartum hemorrhage without increasing thromboembolic risks.
Last updated: October 2026
13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Preeclampsia with Severe Features & Eclampsia: Pathophysiology & Diagnosis
Preeclampsia is a multisystem gestational disorder characterized by abnormal placental cytotrophoblast invasion, spiral artery remodeling failure, and placental hypoperfusion. This triggers widespread maternal vascular endothelial dysfunction, diffuse microvascular vasospasm, and end-organ ischemia.
Diagnostic Criteria for Severe Features
Preeclampsia is conventionally defined as new-onset hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on two occasions at least 4 hours apart) occurring after 20 weeks of gestation in a previously normotensive patient, accompanied by proteinuria (≥300 mg per 24-hour urine collection or urine protein-to-creatinine ratio ≥0.3 mg/mg). However, in the absence of proteinuria, the presence of new-onset hypertension with any of the following severe features establishes the diagnosis of Preeclampsia with Severe Features :
Severe Hypertension : Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg on two occasions at least 15 minutes apart while resting.
Thrombocytopenia : Platelet count <100,000 cells/mcL.
Impaired Liver Function : Serum transaminases (AST or ALT) elevated to greater than twice the upper limit of normal, or severe persistent right upper quadrant or epigastric pain unresponsive to analgesics and not explained by alternative diagnoses.
Renal Insufficiency : Serum creatinine >1.1 mg/dL, or a doubling of baseline serum creatinine in the absence of preexisting renal disease.
Pulmonary Edema .
New-Onset Persistent Cerebral or Visual Disturbances : Severe throbbing headache unresponsive to medication, scotoma, photopsia, cortical blindness, or altered mental status.
Eclampsia
Eclampsia is defined as the occurrence of new-onset generalized tonic-clonic seizures in a woman with preeclampsia that cannot be attributed to other neurological causes (e.g., intracranial hemorrhage, epilepsy, arteriovenous malformation). While most cases occur intrapartum or within 48 hours postpartum, late postpartum eclampsia can develop up to 4 to 6 weeks after delivery.
Magnesium Sulfate for Neuroprotection & Seizure Management
Magnesium sulfate (MgSO₄) is the undisputed first-line agent for both the prevention and treatment of eclamptic seizures (proven superior to phenytoin, diazepam, and nimodipine in the landmark Collaborative Eclampsia Trial and Magpie Trial). Importantly, magnesium sulfate is not an antihypertensive agent; its therapeutic role is strictly central neuroprotection and anticonvulsant activity.
Mechanism of Action
NMDA Receptor Blockade : Blocks central N-methyl-D-aspartate (NMDA) receptor channels in a voltage-dependent manner, suppressing neuronal excitability and raising seizure threshold.
Cerebral Vasodilation : Promotes smooth muscle relaxation and selective cerebral arteriolar vasodilation, reversing cerebral vasospasm and reducing blood-brain barrier permeability and cerebral edema.
Neuromuscular Junction Inhibition : Decreases presynaptic acetylcholine release at the motor endplate and depresses post-junctional membrane sensitivity.
Standard Dosing Protocol
Loading Dose : 4 to 6 g IV diluted in 100 mL of 0.9% normal saline or D5W, infused intravenously over 15 to 20 minutes .
Maintenance Infusion : 1 to 2 g/hour IV continuous infusion .
Duration : Continued throughout labor and delivery and for at least 24 hours postpartum (or 24 hours after the last recorded seizure).
Recurrent Seizures : If seizures recur during maintenance infusion, administer an additional 2 g IV bolus over 3 to 5 minutes.
Therapeutic Monitoring & Toxicity Spectrum
Magnesium is eliminated exclusively by renal glomerular filtration. In patients with renal insufficiency (serum creatinine >1.1 mg/dL or oliguria <30 mL/hour), magnesium accumulates rapidly, requiring maintenance infusion rate reduction to 1 g/h or frequent serum concentration monitoring.
- Serum Magnesium Concentration Clinical Manifestations & Physiological Effects
- 1.7 to 2.4 mg/dL (0.7-1.0 mmol/L) Normal physiological baseline concentration
- 4.8 to 8.4 mg/dL (2.0-3.5 mmol/L) Target Therapeutic Range for eclampsia prophylaxis/treatment
9.0 to 12.0 mg/dL (3.8-5.0 mmol/L) Loss of Deep Tendon Reflexes (Patellar Reflex) (early clinical herald of toxicity)
About 12 to 18 mg/dL (5.0-7.5 mmol/L) Respiratory Depression / Respiratory Paralysis (respiratory rate <12 breaths/min)
Above about 18 mg/dL (>7.5 mmol/L) Altered cardiac conduction: PR prolongation, QRS widening, severe hypotension
- About 25 to 30 mg/dL or higher (>10 mmol/L) Cardiac Arrest (complete AV block, asystole)
- Emergency Toxicity Reversal
If clinical signs of magnesium toxicity appear (loss of patellar reflexes or respiratory rate <12 breaths/min):
Immediately discontinue the magnesium sulfate infusion .
Administer 10% Calcium Gluconate 1 g (10 mL) IV over 3 to 5 minutes (or Calcium Chloride 1 g IV via central access). Calcium directly antagonizes magnesium at the motor endplate and cardiac sarcolemma.
Provide immediate respiratory support (supplemental oxygen, bag-valve-mask ventilation, or endotracheal intubation if respiratory arrest occurs).
Acute Severe Hypertension Management in Pregnancy
Severe acute maternal hypertension ( systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg ) represents an immediate hypertensive emergency requiring pharmacologic reduction within 30 to 60 minutes . The clinical objective is to lower blood pressure into a safe range ( systolic BP 140-150 mmHg and diastolic BP 90-100 mmHg ) to prevent maternal hemorrhagic stroke, encephalopathy, and placental abruption, while avoiding precipitous drops that compromise uteroplacental perfusion.
- First-Line Antihypertensive Agents ACUTE SEVERE HYPERTENSION IN PREGNANCY (BP ≥160/110)
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Initial Choice: IV Labetalol, IV Hydralazine, or Oral Nifedipine IR │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ┌───────────────────────────────┼───────────────────────────────┐
- ▼ ▼ ▼
- ┌───────────────────────┐ ┌───────────────────────┐ ┌───────────────────────┐
- │ IV LABETALOL │ │ IV HYDRALAZINE │ │ ORAL NIFEDIPINE IR │
- │ • 20 mg IV over 2 min │ │ • 5-10 mg IV over 2m │ │ • 10-20 mg PO capsule │
- │ • Wait 10-20 min │ │ • Wait 20 min │ │ • Wait 20-30 min │
- │ • If BP high: 40 mg IV│ │ • If BP high: 10 mg IV│ │ • If BP high: 20 mg PO│
- │ • Then: 80 mg IV q10m │ │ • Max: 20-30 mg total │ │ • Max: 50 mg initial │
- │ • Max: 220-300 mg │ │ • Caution: tachycardia│ │ • Do NOT bite / chew │
- │ • Avoid in asthma/CHF │ │ and delayed drop │ │ or give sublingually│
- └───────────────────────┘ └───────────────────────┘ └───────────────────────┘
Intravenous Labetalol :
Mechanism : Combined non-selective beta-blocker and selective alpha-1 blocker (alpha-to-beta blockade about 1:7 when given IV). Lowers systemic vascular resistance without reducing cardiac output or uteroplacental blood flow.
Dosing : Initial 20 mg IV bolus over 2 minutes. If BP remains ≥160/110 mmHg after 10 to 20 minutes, administer 40 mg IV , then 80 mg IV every 10 minutes to a maximum cumulative dose of 220 to 300 mg .
Contraindications : Active asthma, severe sinus bradycardia, second- or third-degree heart block, or uncompensated heart failure.
Intravenous Hydralazine :
Mechanism : Direct arteriolar vasodilator.
Dosing : Initial 5 to 10 mg IV over 2 minutes. If BP remains elevated after 20 minutes, administer 10 mg IV . Maximum cumulative dose is 20 to 30 mg .
Clinical Considerations : Slower onset (10-20 minutes) and longer half-life; risk of reflex tachycardia, maternal hypotension, and fetal heart rate decelerations.
Oral Immediate-Release Nifedipine :
Mechanism : Dihydropyridine calcium channel blocker.
Dosing : 10 to 20 mg PO (swallowed whole with water). Repeat with 20 mg PO in 20 to 30 minutes if needed (maximum initial dose 50 mg).
Critical Warning : Capsules must never be bitten, chewed, or administered sublingually ; rapid sublingual absorption can cause catastrophic precipitous hypotension and fetal distress.
Strictly Contraindicated Antihypertensives
ACE Inhibitors (e.g., Lisinopril, Enalaprilat) and Angiotensin Receptor Blockers (ARBs, e.g., Losartan) : Carries an FDA black box warning for fetopathy. Second- and third-trimester exposure causes severe oligohydramnios, fetal renal dysgenesis, anuria, pulmonary hypoplasia, neonatal renal failure, skull hypoplasia, and fetal demise.
Sodium Nitroprusside : Carries high risk of maternal and fetal cyanide toxicity and profound rebound intracranial pressure elevation; restricted strictly to refractory intensive care unit emergencies for ultra-short-term bridge therapy (<4 hours).
Postpartum Hemorrhage (PPH): Stepwise Uterotonic Cascade & TXA
Postpartum hemorrhage (PPH) is defined as a cumulative blood loss ≥1,000 mL or blood loss accompanied by signs or symptoms of hypovolemia (tachycardia, hypotension, tachypnea, oliguria) within 24 hours of delivery. Uterine atony (failure of myometrial contraction after placental detachment) accounts for 70% to 80% of PPH cases.
Stepwise Uterotonic Pharmacotherapy
When uterine atony is identified, fundal massage must be paired immediately with a sequential pharmacologic protocol. Clinicians must select second-line uterotonics based strictly on patient-specific contraindications:
Step & Medication Mechanism of Action Standard Emergency Dosing Strict Contraindications & Clinical Pitfalls
Step 1: Oxytocin (Pitocin) Stimulates oxytocin GPCRs, inducing rhythmic myometrial contractions 10 units IM OR 10 to 40 units in 1,000 mL crystalloid infused at 250-500 mL/h STRICT WARNING: Never administer rapid undiluted IV push boluses . Rapid IV boluses provoke acute peripheral vasodilation, profound hypotension, reflex tachycardia, coronary ischemia, and cardiac collapse.
Step 2: Methylergonovine (Methergine) Ergot alkaloid producing sustained, tetanic uterine smooth muscle contractions 0.2 mg IM every 2 to 4 hours (maximum 5 doses) STRICT CONTRAINDICATION: Hypertension, Preeclampsia, CAD . Intense alpha-adrenergic vasoconstriction causes acute hypertensive crises, intracerebral hemorrhage, and coronary vasospasm.
Step 3: Carboprost Tromethamine (Hemabate) Synthetic Prostaglandin F2α analogue inducing myometrial contraction 250 mcg (0.25 mg) IM or intramyometrially q15-90 min (max 8 doses / 2 mg) STRICT CONTRAINDICATION: Active Asthma . Prostaglandin F2α triggers severe bronchial smooth muscle constriction, precipitating fatal status asthmaticus and pulmonary hypertension. Adverse effects: profuse watery diarrhea.
Step 4: Misoprostol (Cytotec) Synthetic Prostaglandin E1 analogue causing potent myometrial contractions 800 mcg sublingually OR 800 to 1,000 mcg rectally Safe in asthma and hypertension. High incidence of transient hyperthermia (fevers up to 40°C), shivering, and rigors within 1 to 2 hours of administration.
Tranexamic Acid in PPH: The WOMAN Trial
The landmark WOMAN trial (World Maternal Antifibrinolytic trial; 20,060 women with postpartum hemorrhage) established the role of TXA in obstetric resuscitation:
Dose & Timing : Administer 1 g IV infused over 10 minutes within 3 hours of delivery .
Repeat Dose : A second 1 g IV dose is administered if bleeding continues after 30 minutes, or if bleeding restarts within 24 hours of the first dose.
Clinical Benefit : TXA significantly reduced maternal mortality due to bleeding (RR 0.81, 95% CI 0.65-1.00; p=0.045) when administered early, with greatest efficacy seen when given within 1 hour of birth, without any increase in maternal venous thromboembolism, pulmonary embolism, or ischemic stroke.